BIOAGE LABS INC (BIOA) Stock Price, Forecast & Analysis
USA - NASDAQ:BIOA - US09077V1008 - Common Stock
BIOA Key Statistics, Chart & Performance
The current stock price of BIOA is 7.26 USD. In the past month the price increased by 35.7%. In the past year, price decreased by -67.28%.
BIOA Latest News, Press Relases and Analysis
BIOA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.77B |
Related stock screener links
About BIOA
Company Profile
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Company Info
BIOAGE LABS INC
5885 Hollis Street, Suite 370
Emeryville CALIFORNIA H3B 4W8 US
CEO: Fabrice Orecchioni
Employees: 62
Phone: 15108061445
BIOAGE LABS INC / BIOA FAQ
What does BIOAGE LABS INC do?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
What is the current price of BIOA stock?
The current stock price of BIOA is 7.26 USD. The price decreased by -2.81% in the last trading session.
What is the dividend status of BIOAGE LABS INC?
BIOA does not pay a dividend.
How is the ChartMill rating for BIOAGE LABS INC?
BIOA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does BIOAGE LABS INC (BIOA) report earnings?
BIOAGE LABS INC (BIOA) will report earnings on 2026-03-18.
What is the outstanding short interest for BIOAGE LABS INC?
The outstanding short interest for BIOAGE LABS INC (BIOA) is 2.06% of its float.
BIOA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BIOA. When comparing the yearly performance of all stocks, BIOA turns out to be only a medium performer in the overall market: it outperformed 43.85% of all stocks.
BIOA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BIOA. While BIOA has a great health rating, there are worries on its profitability.
BIOA Financial Highlights
Over the last trailing twelve months BIOA reported a non-GAAP Earnings per Share(EPS) of -9.63. The EPS decreased by -6.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.53% | ||
| ROE | -26.81% | ||
| Debt/Equity | 0 |
BIOA Forecast & Estimates
9 analysts have analysed BIOA and the average price target is 8.16 USD. This implies a price increase of 12.4% is expected in the next year compared to the current price of 7.26.